Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHV NASDAQ:GERN NASDAQ:LXRX NASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$4.77-9.8%$4.08$2.00▼$6.15$281.61M2.251.26 million shs2.43 million shsGERNGeron$1.23-4.7%$1.56$1.04▼$2.01$827.56M0.6816.30 million shs10.35 million shsLXRXLexicon Pharmaceuticals$2.14-4.0%$1.76$0.52▼$2.53$990.56M0.973.04 million shs2.23 million shsMNKDMannKind$2.99-3.2%$2.75$2.23▼$6.51$954.66M1.046.66 million shs5.15 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences-9.83%-14.67%-6.47%+12.50%+54.87%GERNGeron-4.65%-11.51%-26.79%-31.67%-3.15%LXRXLexicon Pharmaceuticals-4.04%-7.36%+14.44%+62.12%+299.85%MNKDMannKind-3.24%-11.01%+5.28%-46.03%-31.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$4.77-9.8%$4.08$2.00▼$6.15$281.61M2.251.26 million shs2.43 million shsGERNGeron$1.23-4.7%$1.56$1.04▼$2.01$827.56M0.6816.30 million shs10.35 million shsLXRXLexicon Pharmaceuticals$2.14-4.0%$1.76$0.52▼$2.53$990.56M0.973.04 million shs2.23 million shsMNKDMannKind$2.99-3.2%$2.75$2.23▼$6.51$954.66M1.046.66 million shs5.15 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences-9.83%-14.67%-6.47%+12.50%+54.87%GERNGeron-4.65%-11.51%-26.79%-31.67%-3.15%LXRXLexicon Pharmaceuticals-4.04%-7.36%+14.44%+62.12%+299.85%MNKDMannKind-3.24%-11.01%+5.28%-46.03%-31.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHVAchieve Life Sciences 3.00Buy$14.67207.48% UpsideGERNGeron 2.00Hold$2.50103.25% UpsideLXRXLexicon Pharmaceuticals 2.33Hold$4.55112.62% UpsideMNKDMannKind 2.60Moderate Buy$8.84195.78% UpsideCurrent Analyst Ratings BreakdownLatest ACHV, MNKD, GERN, and LXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026LXRXLexicon Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.30 ➝ $3.105/8/2026ACHVAchieve Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$8.00 ➝ $10.005/7/2026MNKDMannKind HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $10.005/7/2026MNKDMannKind Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$3.50 ➝ $4.755/7/2026MNKDMannKind MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$8.00 ➝ $7.004/28/2026MNKDMannKind Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $8.004/27/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/24/2026ACHVAchieve Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026ACHVAchieve Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$13.004/20/2026ACHVAchieve Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHVAchieve Life SciencesN/AN/AN/AN/A$0.40 per shareN/AGERNGeron$183.88M4.29N/AN/A$0.35 per share3.51LXRXLexicon Pharmaceuticals$69.64M13.65N/AN/A$0.30 per share7.13MNKDMannKind$348.97M2.65$0.06 per share49.94($0.17) per share-17.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHVAchieve Life Sciences-$54.65M-$1.12N/AN/AN/AN/A-193.49%-111.88%8/6/2026 (Estimated)GERNGeron-$83.50M-$0.11N/A12.30N/A-35.48%-23.31%-10.08%8/5/2026 (Estimated)LXRXLexicon Pharmaceuticals-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%8/5/2026 (Estimated)MNKDMannKind$5.86M-$0.07N/A19.93N/A-6.63%-11.21%-3.92%8/5/2026 (Estimated)Latest ACHV, MNKD, GERN, and LXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ACHVAchieve Life Sciences-$0.30-$0.19+$0.11-$0.19N/AN/A5/7/2026Q1 2026LXRXLexicon Pharmaceuticals-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million5/6/2026Q1 2026GERNGeron-$0.03-$0.01+$0.02-$0.01$50.59 million$51.84 million5/6/2026Q1 2026MNKDMannKind-$0.02-$0.05-$0.03-$0.05$105.38 million$90.17 million3/24/2026Q4 2025ACHVAchieve Life Sciences-$0.27-$0.28-$0.01-$0.28N/AN/A3/5/2026Q4 2025LXRXLexicon Pharmaceuticals-$0.07-$0.04+$0.03-$0.04$3.14 million$5.49 million2/26/2026Q4 2025MNKDMannKind-$0.01-$0.05-$0.04-$0.05$99.85 million$111.96 million2/25/2026Q4 2025GERNGeron-$0.03-$0.05-$0.02-$0.05$50.43 million$48.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACHVAchieve Life SciencesN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHVAchieve Life Sciences0.872.622.62GERNGeron0.526.784.96LXRXLexicon Pharmaceuticals0.2418.8018.77MNKDMannKindN/A1.871.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHVAchieve Life Sciences33.52%GERNGeron73.71%LXRXLexicon Pharmaceuticals74.70%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipACHVAchieve Life Sciences3.00%GERNGeron1.71%LXRXLexicon Pharmaceuticals14.00%MNKDMannKind2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHVAchieve Life Sciences2053.23 million51.64 millionOptionableGERNGeron70641.52 million630.55 millionOptionableLXRXLexicon Pharmaceuticals140444.20 million382.01 millionOptionableMNKDMannKind400308.95 million300.92 millionOptionableACHV, MNKD, GERN, and LXRX HeadlinesRecent News About These CompaniesMannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2MMay 18 at 2:11 AM | insidermonkey.comHC Wainwright Brokers Raise Earnings Estimates for MannKindMay 18 at 1:44 AM | americanbankingnews.comFY2026 EPS Estimates for MannKind Increased by HC WainwrightMay 18 at 1:40 AM | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Given Average Rating of "Moderate Buy" by AnalystsMay 15, 2026 | americanbankingnews.comSteven Binder Sells 16,940 Shares of MannKind (NASDAQ:MNKD) StockMay 14, 2026 | insidertrades.comWells Fargo Raises its Price Target on MannKind (MNKD) to $10May 13, 2026 | insidermonkey.comH.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price TargetsMay 11, 2026 | insidermonkey.comMannKind (NASDAQ:MNKD) Downgraded to "Sell" Rating by Wall Street ZenMay 9, 2026 | americanbankingnews.comWall Street Zen Downgrades MannKind (NASDAQ:MNKD) to SellMay 9, 2026 | marketbeat.comMannKind: Q1 Earnings SnapshotMay 8, 2026 | stamfordadvocate.comSMannKind drops after Q1 missMay 8, 2026 | seekingalpha.comMannKind targets $110M-$120M 2026 FUROSCIX revenue as it nears May 29 and July 26 PDUFA catalystsMay 8, 2026 | msn.comMannKind (NASDAQ:MNKD) Price Target Lowered to $7.00 at MizuhoMay 8, 2026 | americanbankingnews.comMannKind Leans Into Growth Amid Earnings VolatilityMay 7, 2026 | tipranks.comMannKind (NASDAQ:MNKD) Price Target Raised to $4.75May 7, 2026 | marketbeat.comMannKind: It's ComplicatedMay 7, 2026 | seekingalpha.comMannKind (NASDAQ:MNKD) Given New $7.00 Price Target at MizuhoMay 7, 2026 | marketbeat.comMannKind Corporation 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comMannKind (NASDAQ:MNKD) Announces Earnings Results, Misses Estimates By $0.03 EPSMay 6, 2026 | marketbeat.comMannKind Q1 Earnings Call HighlightsMay 6, 2026 | marketbeat.comCompared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key MetricsMay 6, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACHV, MNKD, GERN, and LXRX Company DescriptionsAchieve Life Sciences NASDAQ:ACHV$4.77 -0.52 (-9.83%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$4.84 +0.07 (+1.36%) As of 05/18/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Geron NASDAQ:GERN$1.23 -0.06 (-4.65%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$1.25 +0.02 (+1.22%) As of 05/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Lexicon Pharmaceuticals NASDAQ:LXRX$2.14 -0.09 (-4.04%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$2.13 -0.01 (-0.23%) As of 05/18/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.MannKind NASDAQ:MNKD$2.99 -0.10 (-3.24%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$3.02 +0.03 (+1.17%) As of 05/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom MarketBeat Week in Review – 05/11 - 05/15 Insider Buying Says Upstart Isn’t Down for the Count Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
